Dupilumab in the treatment of genodermatosis: A systematic review

Po Chien Wu, Ying Xiu Dai, Chia Lun Li, Chih Chiang Chen, Yun Ting Chang, Sheng Hsiang Ma*

*此作品的通信作者

研究成果: Review article同行評審

6 引文 斯高帕斯(Scopus)

摘要

Dupilumab interferes with the signaling pathways of IL-4 and IL-13 and is effective in treating atopic dermatitis. Specific genodermatoses, including Netherton syndrome, epidermolysis bullosa pruriginosa, and hyper-IgE syndrome, are Th2 skewed diseases with activation of type 2 inflammation. We performed this systematic review to investigate the therapeutic role of dupilumab in the treatment of genodermatosis. A systematic search was conducted of the PubMed, Embase, Web of Science, and Cochrane databases from inception to December 13, 2021. The review included studies with relevant terms including “dupilumab,” “genodermatosis”, “Netherton syndrome”, “ichthyosis”, “epidermolysis bullosa” and “hyper-IgE syndrome”. The initial search yielded 2,888 results, of which 28 studies and 37 patients with genodermatosis were enrolled. The assessed genodermatoses included Netherton syndrome, epidermolysis bullosa pruriginosa, hyper-IgE syndrome, Hailey-Hailey disease, and severe eczema associated with genetic disorders. Most of the reported cases showed significant clinical improvement after the initiation of dupilumab treatment without major adverse events. Decreased immunoglobulin E levels and cytokine normalization have also been documented. In conclusion, Dupilumab may have a potential therapeutic role in certain genodermatoses skewed towards T helper 2 (Th2) immunity, including Netherton syndrome, epidermolysis bullosa pruriginosa, hyper-IgE syndrome, Hailey-Hailey disease, and severe eczema associated with some genetic disorders.

原文English
頁(從 - 到)7-17
頁數11
期刊JDDG - Journal of the German Society of Dermatology
21
發行號1
DOIs
出版狀態Published - 1月 2023

指紋

深入研究「Dupilumab in the treatment of genodermatosis: A systematic review」主題。共同形成了獨特的指紋。

引用此